GlassScriptPhysician profile
Kimberly Stump
NPI 1770129835
$1,171.52
in general payments reported to CMS, 2019-2025
16 companies · $302 in 2025
The $302 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $184 · 2023: $588 · 2024: $97.63 · 2025: $302.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $988.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $987.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $303.90 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $219.32 | 2022-2025 | Entyvio, Gattex |
| Pfizer INC. | $123.69 | 2022-2025 | |
| Genzyme Corporation | $119.75 | 2023-2025 | |
| Intercept Pharmaceuticals, INC. | $88.50 | 2023 | Ocaliva |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $70.84 | 2022-2025 | Xifaxan |
| Evoke Pharma, INC. | $47.14 | 2022-2025 | Gimoti |
| Sandoz INC. | $36.59 | 2023 | Hyrimoz |
| Merck Sharp & Dohme LLC | $32.46 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $24.74 | 2024 | Dupixent |
| Madrigal Pharmaceuticals | $20.44 | 2025 | Rezdiffra |
| Axonics, INC. | $20.06 | 2024 | Axonics |
| Celltrion USA INC. | $18.88 | 2025 | Vegzelma |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.38 | 2023 | Cyltezo |
| Nestle Healthcare Nutrition INC. | $14.84 | 2023 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $12.99 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Stump listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.